Stacy Smith, MD
Neuro-ophthalmology · Bellaire, TXNPI 1306138235
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,564 of the $224,723 with a category attached, or 79.0%. 52 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.1% of the total. Reporting peaked in 2020 at $78,515 and has fallen 58.1% since, to $32,889 in 2025.
Across 902 payments — averaging $249.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$70K
- Lilly USA, LLC$65K
- Pfizer$41K
- AbbVie$24K
- Biohaven Pharmaceutical Holding Company Ltd.$18K
- AstraZeneca$937
- plus $6K from 46 others
What the payments were for
- Consulting fees$18,4838%
- Speaking & faculty fees$177,56479%
- Grants$440%
- Travel & lodging$11,3355%
- Food & beverage$17,2908%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuro-ophthalmology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 80 | $141,790 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $59,870 |
| UbrelvyUbrogepant | 42 | $59,794 |
| QuliptaAtogepant | 52 | $56,674 |
| Emgality PenGalcanezumab-Gnlm | 52 | $42,348 |
| BotoxOnabotulinumtoxina | 11 | $14,348 |
| Eletriptan HbrEletriptan Hydrobromide | 37 | $2,585 |
| Sumatriptan Succinate | 79 | $2,010 |
| Carbamazepine ErCarbamazepine | 11 | $1,902 |
| RizatriptanRizatriptan Benzoate | 70 | $1,428 |
| Topiramate | 88 | $1,185 |
| Gabapentin | 75 | $997 |
| Cyclobenzaprine Hcl | 60 | $749 |
| Pyridostigmine Bromide | 15 | $731 |
| Amitriptyline Hcl | 82 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $40,817 | $141,79080 claims |
| AbbVieUbrelvy, Qulipta, Botox | $23,975 | $130,816105 claims |
| Upsher-smith Laboratories LLCTopiramate | $96 | $1,18588 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $116 | $73115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuro-ophthalmology providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuro-ophthalmology in Bellaire
- Ore Ofeoluwatomi AdesinaHouston$2K
- Melanie Truong-LeDallas$729
- Noor LaylaniHouston$439
- Amy DurandAustin$309
- Angela KimSan Antonio$219
- Sergio Garces UribeDallas$200
- Subahari RaviskanthanHouston$139
- Emely Karam AguilarSan Antonio$65
- Robert HoganDallas$52
- Ruben JaureguiDallas$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.